Abstract
The main objective of these studies was to investigate whether the nanoparticle delivery has any immunopotentiation effect at modest doses of a few micro- or nanograms of CpG oligodeoxynucleotide (CpG ODN) and what would be the influence on T cell responses at such low doses. Various doses (5 to 0.05 μg) of a model CpG ODN adjuvant (ܢ) along with 2 Lf tetanus toxoid (TT) were formulated in either nanoparticles using poly(D,L-lactic-coglycolic acid) (PLGA) 50:50 co-polymer, or saline. Strong antigen specific ex vivo T cell proliferation was observed for the Balb / c mice receiving immunogens in nanoparticles. At 5 μg dose of CpG ODN, the T cell stimulation index (SI) was 241 as compared with 74 for the same dose when given in saline. Comparable SI value of 78 was observed at 100-fold lower dose (0.05 μg) using nanoparticles. Similarly, significantly higher (P < 0.01) cytokine secretion was observed for nanoparticles groups. A ten-fold lower dose (0.5 μg instead of 5 μg) of CpG ODN in nanoparticles was adequate to obtain levels of IFN-γ, TNF-α, and IL-2 comparable to those observed following immunisations in saline. The immunopotentiation effect of the particulate delivery on antibody response (total IgG and subtypes) was not so marked. These studies emphasise that antigen delivery in biodegradable nanoparticles can facilitate induction of strong T cell responses, particularly of the Th1 type, at extremely lower doses of CpG ODN. Such reduction in the effective dose would be advantageous for minimising the potential side effects of these novel adjuvants.
Keywords: cpg dna, immunostimulatory cpg motifs, nanospheres, vaccine delivery, plga
Current Drug Delivery
Title: Dose Sparing of CpG Oligodeoxynucleotide Vaccine Adjuvants by Nanoparticle Delivery
Volume: 1 Issue: 4
Author(s): Manish Diwan, Praveen Elamanchili, Min Cao and John Samuel
Affiliation:
Keywords: cpg dna, immunostimulatory cpg motifs, nanospheres, vaccine delivery, plga
Abstract: The main objective of these studies was to investigate whether the nanoparticle delivery has any immunopotentiation effect at modest doses of a few micro- or nanograms of CpG oligodeoxynucleotide (CpG ODN) and what would be the influence on T cell responses at such low doses. Various doses (5 to 0.05 μg) of a model CpG ODN adjuvant (ܢ) along with 2 Lf tetanus toxoid (TT) were formulated in either nanoparticles using poly(D,L-lactic-coglycolic acid) (PLGA) 50:50 co-polymer, or saline. Strong antigen specific ex vivo T cell proliferation was observed for the Balb / c mice receiving immunogens in nanoparticles. At 5 μg dose of CpG ODN, the T cell stimulation index (SI) was 241 as compared with 74 for the same dose when given in saline. Comparable SI value of 78 was observed at 100-fold lower dose (0.05 μg) using nanoparticles. Similarly, significantly higher (P < 0.01) cytokine secretion was observed for nanoparticles groups. A ten-fold lower dose (0.5 μg instead of 5 μg) of CpG ODN in nanoparticles was adequate to obtain levels of IFN-γ, TNF-α, and IL-2 comparable to those observed following immunisations in saline. The immunopotentiation effect of the particulate delivery on antibody response (total IgG and subtypes) was not so marked. These studies emphasise that antigen delivery in biodegradable nanoparticles can facilitate induction of strong T cell responses, particularly of the Th1 type, at extremely lower doses of CpG ODN. Such reduction in the effective dose would be advantageous for minimising the potential side effects of these novel adjuvants.
Export Options
About this article
Cite this article as:
Diwan Manish, Elamanchili Praveen, Cao Min and Samuel John, Dose Sparing of CpG Oligodeoxynucleotide Vaccine Adjuvants by Nanoparticle Delivery, Current Drug Delivery 2004; 1 (4) . https://dx.doi.org/10.2174/1567201043334597
DOI https://dx.doi.org/10.2174/1567201043334597 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo
Mini-Reviews in Medicinal Chemistry Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Impact of Nutrients on the Functioning of Intestinal Goblet Cells: Health and Therapeutic Perspectives
Current Nutrition & Food Science Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Biological Markers in Older People at Risk of Mobility Limitations
Current Pharmaceutical Design Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science Gene Therapy for Arthritis
Current Drug Targets Is Inflammation a Common Retinal-Renal-Nerve Pathogenic Link in Diabetes?
Current Diabetes Reviews Vitamin D Deficiency and Acute Lung Injury
Inflammation & Allergy - Drug Targets (Discontinued) Toxic Effects of Aflatoxin B1 on Embryonic Development of Zebrafish (Danio rerio): Potential Activity of Piceatannol Encapsulated Chitosan/poly (Lactic Acid) Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry An Update On Proficiency of Voltage-gated Ion Channel Blockers in the Treatment of Inflammation-associated Diseases
Current Drug Targets Assessment of Signal Peptides to Optimize Interleukin 2 (IL-2) Folding and Expression
Current Proteomics TRPV4 Agonists and Antagonists
Current Topics in Medicinal Chemistry Altering Landscape of Cancer Vaccines: Unique Platforms, Research on Therapeutic Applications and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders